Skip to content
10-K

Annual Report

Zentalis Pharmaceuticals, Inc. ZNTL

0001725160-26-000014

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 20, 2026 70.93M sh
Shares Diluted FY 2025 · Dec 31, 2025 71.87M sh
Shares Diluted FY 2025 · Dec 31, 2024 71.08M sh
Shares Diluted FY 2025 · Dec 31, 2023 65.41M sh
Stock Repurchased FY 2025 · Dec 31, 2025 $9.98M
Stock Repurchased FY 2025 · Dec 31, 2024 $0
Stock Repurchased FY 2025 · Dec 31, 2023 $0
Capex FY 2025 · Dec 31, 2025 $0
Capex FY 2025 · Dec 31, 2024 $221K
Capex FY 2025 · Dec 31, 2023 $583K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$125.25M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$170.86M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$207.82M
Cash And Equivalents FY 2025 · Dec 31, 2025 $36M
Cash And Equivalents FY 2025 · Dec 31, 2024 $33.9M
Cash And Equivalents FY 2025 · Dec 31, 2023 $28.04M
Stockholders Equity FY 2025 · Dec 31, 2025 $216.2M
Stockholders Equity FY 2025 · Dec 31, 2024 $337.19M
Current Liabilities FY 2025 · Dec 31, 2025 $36.56M
Current Liabilities FY 2025 · Dec 31, 2024 $52.73M
Total Liabilities FY 2025 · Dec 31, 2025 $72.76M
Total Liabilities FY 2025 · Dec 31, 2024 $93.15M
Current Assets FY 2025 · Dec 31, 2025 $253.19M
Current Assets FY 2025 · Dec 31, 2024 $386.07M
Total Assets FY 2025 · Dec 31, 2025 $288.97M
Total Assets FY 2025 · Dec 31, 2024 $430.34M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.91
Eps Diluted FY 2025 · Dec 31, 2024 −$2.33
Eps Diluted FY 2025 · Dec 31, 2023 −$4.47
Eps Basic FY 2025 · Dec 31, 2025 −$1.91
Eps Basic FY 2025 · Dec 31, 2024 −$2.33
Eps Basic FY 2025 · Dec 31, 2023 −$4.47
Sga Expense FY 2025 · Dec 31, 2025 $37.72M
Sga Expense FY 2025 · Dec 31, 2024 $87.12M
Sga Expense FY 2025 · Dec 31, 2023 $64.35M
Rd Expense FY 2025 · Dec 31, 2025 $107.3M
Rd Expense FY 2025 · Dec 31, 2024 $167.77M
Rd Expense FY 2025 · Dec 31, 2023 $189.59M
Net Income FY 2025 · Dec 31, 2025 −$137.06M
Net Income FY 2025 · Dec 31, 2024 −$165.84M
Net Income FY 2025 · Dec 31, 2023 −$292.19M
Operating Income FY 2025 · Dec 31, 2025 −$152.81M
Operating Income FY 2025 · Dec 31, 2024 −$191.19M
Operating Income FY 2025 · Dec 31, 2023 −$299.51M
Revenue FY 2025 · Dec 31, 2025 $0
Revenue FY 2025 · Dec 31, 2024 $67.43M
Revenue FY 2025 · Dec 31, 2023 $0